Zhuhai Rundu Pharmaceutical Co Ltd Class A (SHE:002923) — Market Cap & Net Worth
Market Cap & Net Worth: Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923)
Zhuhai Rundu Pharmaceutical Co Ltd Class A (SHE:002923) has a market capitalization of $535.14 Million (CN¥3.66 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #12002 globally and #3466 in its home market, demonstrating a 0.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhuhai Rundu Pharmaceutical Co Ltd Class A's stock price CN¥10.92 by its total outstanding shares 334893286 (334.89 Million). Also see Zhuhai Rundu Pharmaceutical Co Ltd Class assets under control for a full breakdown of the balance sheet.
Zhuhai Rundu Pharmaceutical Co Ltd Class A Market Cap History: 2018 to 2026
Zhuhai Rundu Pharmaceutical Co Ltd Class A's market capitalization history from 2018 to 2026. Data shows growth from $370.35 Million to $535.14 Million (6.27% CAGR). Also see Zhuhai Rundu Pharmaceutical Co Ltd Class (002923) cash flow conversion for how efficiently the company converts equity into cash flow.
Zhuhai Rundu Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhuhai Rundu Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 002923 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.51x
Zhuhai Rundu Pharmaceutical Co Ltd Class A's market cap is 0.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $370.35 Million | $1.04 Billion | $106.84 Million | 0.35x | 3.47x |
| 2019 | $419.84 Million | $1.36 Billion | $118.90 Million | 0.31x | 3.53x |
| 2020 | $397.81 Million | $1.25 Billion | $135.86 Million | 0.32x | 2.93x |
| 2021 | $616.42 Million | $1.19 Billion | $139.77 Million | 0.52x | 4.41x |
| 2022 | $586.10 Million | $1.37 Billion | $155.48 Million | 0.43x | 3.77x |
| 2023 | $593.39 Million | $1.29 Billion | $66.90 Million | 0.46x | 8.87x |
| 2024 | $467.51 Million | $1.18 Billion | $39.88 Million | 0.40x | 11.72x |
| 2025 | $595.42 Million | $1.18 Billion | -$63.47 Million | 0.51x | N/A |
Competitor Companies of 002923 by Market Capitalization
Companies near Zhuhai Rundu Pharmaceutical Co Ltd Class A in the global market cap rankings as of September 19, 2026. Review tangible net worth ratio of Zhuhai Rundu Pharmaceutical Co Ltd Class to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Zhuhai Rundu Pharmaceutical Co Ltd Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Zhuhai Rundu Pharmaceutical Co Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Zhuhai Rundu Pharmaceutical Co Ltd Class A's market cap moved from $370.35 Million to $ 535.14 Million, with a yearly change of 6.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥535.14 Million | -10.12% |
| 2025 | CN¥595.42 Million | +27.36% |
| 2024 | CN¥467.51 Million | -21.21% |
| 2023 | CN¥593.39 Million | +1.24% |
| 2022 | CN¥586.10 Million | -4.92% |
| 2021 | CN¥616.42 Million | +54.95% |
| 2020 | CN¥397.81 Million | -5.25% |
| 2019 | CN¥419.84 Million | +13.36% |
| 2018 | CN¥370.35 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Zhuhai Rundu Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $535.14 Million USD |
| MoneyControl | $535.14 Million USD |
| MarketWatch | $535.14 Million USD |
| marketcap.company | $535.14 Million USD |
| Reuters | $535.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular, gastrointestinal, antibiotics, analgetic and antipyretics, anti-virus, endocrinology, and respiratory; and pellets for excipient, antiulcerative, diabetes … Read more